Hologic, Inc. (NASDAQ:HOLX) Receives $88.92 Consensus Target Price from Analysts

Shares of Hologic, Inc. (NASDAQ:HOLX) have received a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the company, Marketbeat reports. Seven analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $88.92.

HOLX has been the subject of a number of analyst reports. Jefferies Financial Group initiated coverage on Hologic in a research report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective for the company. Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Leerink Partners reduced their price objective on Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. BNP Paribas raised Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Raymond James lifted their target price on Hologic from $93.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.88% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Prentiss Smith & Co. Inc. grew its holdings in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock valued at $3,967,000 after buying an additional 130 shares in the last quarter. Covestor Ltd grew its stake in Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after purchasing an additional 133 shares in the last quarter. First Horizon Advisors Inc. grew its stake in Hologic by 38.3% in the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 134 shares in the last quarter. Brooklyn Investment Group grew its stake in Hologic by 14.7% in the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares in the last quarter. Finally, Empirical Finance LLC grew its stake in Hologic by 1.8% in the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after purchasing an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX opened at $71.19 on Thursday. The firm has a market cap of $16.07 billion, a price-to-earnings ratio of 21.38, a PEG ratio of 2.38 and a beta of 0.97. The stock has a 50 day moving average of $74.30 and a 200-day moving average of $78.31. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic has a 52 week low of $68.61 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the firm posted $0.89 EPS. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, analysts forecast that Hologic will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.